WO2001089558A3 - Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states - Google Patents

Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states Download PDF

Info

Publication number
WO2001089558A3
WO2001089558A3 PCT/US2001/011771 US0111771W WO0189558A3 WO 2001089558 A3 WO2001089558 A3 WO 2001089558A3 US 0111771 W US0111771 W US 0111771W WO 0189558 A3 WO0189558 A3 WO 0189558A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
zymogen
formulations
hypercoagulable states
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/011771
Other languages
French (fr)
Other versions
WO2001089558A2 (en
Inventor
Charles Jack Fisher
Sau-Chi Betty Yan
Brian Paul Barrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to EP01937176A priority Critical patent/EP1289543A2/en
Priority to JP2001585801A priority patent/JP2004511428A/en
Priority to AU2001262939A priority patent/AU2001262939A1/en
Priority to CA002410567A priority patent/CA2410567A1/en
Priority to US10/276,771 priority patent/US7087578B2/en
Publication of WO2001089558A2 publication Critical patent/WO2001089558A2/en
Publication of WO2001089558A3 publication Critical patent/WO2001089558A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method of treating a human patient with a hypercoagulable state or protein C deficiency, which comprises administering activated Protein C and protein C Zymogen.
PCT/US2001/011771 2000-05-24 2001-05-14 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states Ceased WO2001089558A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01937176A EP1289543A2 (en) 2000-05-24 2001-05-14 Formulations and methods for treating hypercoagulable states
JP2001585801A JP2004511428A (en) 2000-05-24 2001-05-14 Formulations and methods for treating hypercoagulable conditions
AU2001262939A AU2001262939A1 (en) 2000-05-24 2001-05-14 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
CA002410567A CA2410567A1 (en) 2000-05-24 2001-05-14 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
US10/276,771 US7087578B2 (en) 2000-05-24 2001-05-14 Formulations and methods for treating hypercoagulable states

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20673300P 2000-05-24 2000-05-24
US60/206,733 2000-05-24

Publications (2)

Publication Number Publication Date
WO2001089558A2 WO2001089558A2 (en) 2001-11-29
WO2001089558A3 true WO2001089558A3 (en) 2002-09-12

Family

ID=22767701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011771 Ceased WO2001089558A2 (en) 2000-05-24 2001-05-14 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states

Country Status (6)

Country Link
US (1) US7087578B2 (en)
EP (1) EP1289543A2 (en)
JP (1) JP2004511428A (en)
AU (1) AU2001262939A1 (en)
CA (1) CA2410567A1 (en)
WO (1) WO2001089558A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024215A2 (en) * 2000-09-18 2002-03-28 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
WO2004052281A2 (en) * 2002-12-06 2004-06-24 Agennix Incorporated Oral lactoferrin in the treatment of sepsis
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
BRPI0808259A2 (en) * 2007-03-05 2014-07-08 Cadila Healthcare Ltd. , "FORMULATION, LYOPHILIZATION PROCESS, LYOPHILIZED FORMULATION, AND PROCESS TO PREPARE LYOPHILIZED FORMULATION"
ES2618899T3 (en) * 2010-02-26 2017-06-22 The Children's Hospital Of Philadelphia Protein C Zimmogen and methods of using it to prevent cancer metastases
ES2609070T3 (en) * 2013-02-28 2017-04-18 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
US11844808B2 (en) * 2018-01-16 2023-12-19 Women & Infants Hospital Of Rhode Island Methods and compositions for treating pre-eclampsia
EP4053559A1 (en) * 2021-03-01 2022-09-07 Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER) Methods for the measurement of protein c and activated protein c

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
EP0875252A2 (en) * 1997-04-28 1998-11-04 Eli Lilly And Company Activated protein C formulations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (en) 1986-03-27 1995-03-27 Vukovich Thomas Dr METHOD FOR SEPARATING PROTEINS BY MEANS OF GRADIENT ELUTION AND DEVICE FOR IMPLEMENTING THE METHOD
US5175087A (en) 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5009889A (en) 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
JP2739050B2 (en) 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 Anticoagulant
JPH01226900A (en) 1988-03-08 1989-09-11 Green Cross Corp:The Method for purifying protein c
DE3823519A1 (en) 1988-07-12 1990-01-18 Basf Ag Process for the purification of activated protein C
GB8819607D0 (en) 1988-08-17 1988-09-21 Wellcome Found Novel combination
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
WO1991012320A1 (en) 1990-02-09 1991-08-22 Zymogenetics, Inc. Activated protein c with truncated light chain
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli Method for producing a polypeptide in a eukaryotic host cell and recombinant dna vectors containing an improved transcription control unit based on the adenovirus 2 major late promoter used thereto
AT402262B (en) 1991-06-20 1997-03-25 Immuno Ag MEDICINAL ACTIVATED PROTEIN C
US5413732A (en) 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
JP3434326B2 (en) 1992-08-25 2003-08-04 財団法人化学及血清療法研究所 Agent for prevention and treatment of adult respiratory distress syndrome (ARDS)
DE4234295A1 (en) 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carboxylic acid derivatives, medicaments containing these compounds and process for their preparation
US5395923A (en) 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
US5453523A (en) 1993-06-16 1995-09-26 Emulsion Technology, Inc. Process for obtaining highly purified phosphatidylcholine
JP2825739B2 (en) 1993-09-20 1998-11-18 帝人株式会社 Acute liver failure treatment
JP3043558B2 (en) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 Preparation of human activated protein C and method for its preparation
JP2886061B2 (en) 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 Method and composition for stabilizing protein C or activated protein C
JPH07165605A (en) 1993-12-16 1995-06-27 Teijin Ltd Activated protein C vial
NZ270271A (en) 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (en) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd Preventive and therapeutic agents for absorbable bone diseases
JP3802104B2 (en) 1995-05-31 2006-07-26 財団法人化学及血清療法研究所 Preventive and therapeutic agents for neuropathy associated with spinal cord injury
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
EP0875252A2 (en) * 1997-04-28 1998-11-04 Eli Lilly And Company Activated protein C formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1289543A2 *

Also Published As

Publication number Publication date
US20030211969A1 (en) 2003-11-13
EP1289543A2 (en) 2003-03-12
WO2001089558A2 (en) 2001-11-29
CA2410567A1 (en) 2001-11-29
JP2004511428A (en) 2004-04-15
AU2001262939A1 (en) 2001-12-03
US7087578B2 (en) 2006-08-08

Similar Documents

Publication Publication Date Title
MXPA03007816A (en) Disposable underpants and method of providing the same.
EP1550456A3 (en) Use of botulinum toxin in the treatment of burn pain
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
AU5788300A (en) Medical treatment method and kit
AU2002216273A1 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
HUP9902867A3 (en) Therapeutic use of vegf protein or nucleic acid coding same and implant, especially for the treatment of intimal hyperplasia
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
WO2001028494A3 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
AUPR839001A0 (en) Dosage form, device and methods of treatment
AU2001249389A1 (en) Modified blood clotting factors and methods of use
HK1047707A1 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
WO2003062273A3 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
AU2001264042A1 (en) 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
WO2002005848A3 (en) Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
WO2003063725A3 (en) Methods of preventing and treating flavivirus infection in animals
WO2001089558A3 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
AU2002230748A1 (en) Method and catheter for aerating fluids for medical uses
AU6887101A (en) Copolymers and methods of treating prion-related diseases
WO2001051072A3 (en) Antiparasitic agent
AU2002245204A1 (en) Methods for treating blood coagulation disorders
AU2001234831A1 (en) Magnetoliposome composition for targeted treatment of biological tissue and associated methods
AU4204700A (en) Compounds and methods for the diagnosis and treatment of (b. microti) infection
AU2001237543A1 (en) Proteins, genes and their use for diagnosis and treatment of schizophrenia
AU2001242490A1 (en) Device for treating human and/or animal tissue

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10276771

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001937176

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2410567

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001937176

Country of ref document: EP